Measovir®-based candidate

About Oncovita

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

About Oncovita

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

About Oncovita

Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.

Therapeutic Areas